Purespring Therapeutics

Biotech · London, GB

Gene therapies for kidney diseases via AAV platform targeting podocytes.

Founders

Moin Saleem (United Kingdom · ♂) — A world-leading kidney specialist and academic nephrologist at the University of Bristol, Saleem founded Purespring (launched with Syncona in 2020) to translate his research on the podocyte kidney cell into AAV gene therapies delivered directly to the kidney.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Oct 2024	Series B London gene-therapy startup Purespring Therapeutics raised an £80M Series B led by Sofinnova Partners to advance its kidney-disease pipeline.	$104M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.